- Home
- LLYVA vs HALO Comparison
LLYVA vs HALO Comparison
Compare LLYVA & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LLYVA
- HALO
- Stock Information
- Founded
- LLYVA 1991
- HALO 1998
- Country
- LLYVA United States
- HALO United States
- Employees
- LLYVA N/A
- HALO N/A
- Industry
- LLYVA Broadcasting
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LLYVA Industrials
- HALO Health Care
- Exchange
- LLYVA Nasdaq
- HALO Nasdaq
- Market Cap
- LLYVA 6.3B
- HALO 6.4B
- IPO Year
- LLYVA N/A
- HALO N/A
- Fundamental
- Price
- LLYVA $70.10
- HALO $48.60
- Analyst Decision
- LLYVA
- HALO Buy
- Analyst Count
- LLYVA 0
- HALO 9
- Target Price
- LLYVA N/A
- HALO $61.11
- AVG Volume (30 Days)
- LLYVA 118.8K
- HALO 1.5M
- Earning Date
- LLYVA 01-01-0001
- HALO 10-31-2024
- Dividend Yield
- LLYVA N/A
- HALO N/A
- EPS Growth
- LLYVA N/A
- HALO 61.71
- EPS
- LLYVA N/A
- HALO 3.02
- Revenue
- LLYVA N/A
- HALO $947,355,000.00
- Revenue This Year
- LLYVA N/A
- HALO $23.36
- Revenue Next Year
- LLYVA $11.15
- HALO $15.15
- P/E Ratio
- LLYVA N/A
- HALO $16.09
- Revenue Growth
- LLYVA N/A
- HALO 21.35
- 52 Week Low
- LLYVA $32.55
- HALO $33.15
- 52 Week High
- LLYVA $72.88
- HALO $65.53
- Technical
- Relative Strength Index (RSI)
- LLYVA 62.57
- HALO 45.95
- Support Level
- LLYVA $68.73
- HALO $47.31
- Resistance Level
- LLYVA $70.61
- HALO $48.88
- Average True Range (ATR)
- LLYVA 1.53
- HALO 1.23
- MACD
- LLYVA -0.76
- HALO 0.26
- Stochastic Oscillator
- LLYVA 33.97
- HALO 56.09
About LLYVA Liberty Media Corporation Series A Liberty Live
Liberty Live Group would be engaged in the operations of Live Nation, and Liberty Media's strategy for that group is to maximize the value of its investment in that company and the other assets attributed to the Liberty Live Group and to use the new Liberty Live common stock to make strategic acquisitions or for other capital raising initiatives.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.